The present invention is directed to the treatment of diabetic nephropathy with a) a phosphodiesterase 4 inhibitor, b) a combination of a phosphodiesterase 4 inhibitor with an AT1 angiotensin II receptor antagonist or c) a combination of a phosphodiesterase 4 inhibitor with an angiotensin-converting enzyme inhibitor.